“This quarter we made excellent progress in our development of verekitug, positioning us well to deliver on our upcoming clinical milestones. We are pleased to accelerate our guidance on several near-term events, including the top-line data readout from our Phase 2 clinical trial of verekitug in patients with CRSwNP, expected in the third quarter of this year,” said Rand Sutherland, MD, Chief Executive Officer of Upstream Bio (UPB). “In addition, we now anticipate reporting top-line data from our Phase 2 clinical trial in severe asthma in the first half of 2026. We also now expect to dose the first patient in our Phase 2 clinical trial in COPD in mid-2025. We look forward to sharing further updates as we reach these key milestones.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UPB:
- Upstream Bio, Inc.: Promising Outlook with Strategic Positioning and Strong Trial Execution
- Upstream Bio’s Financial Results and Strategic Progress
- Promising Developments and Strong Financial Position Drive Buy Rating for Upstream Bio, Inc.
- Buy Rating for Upstream Bio: Promising Clinical Progress and Unique Drug Candidate Potential
- Upstream Bio reports Q4 revenue $613k, consensus $384.75k